Here are five things to know:
1. Northland Securities will now cover K2M.
2. The company issued an “outperform” rating.
3. The price objective on the stock is $31.
4. Barclays also raised K2M’s price target from $27 to $28.
5. K2M’s market cap is $988.2 million.
More articles on orthopedic devices:
LDR gets “Outperform” rating—5 key notes
Spinal Kinetics M6 disc replacement: Grood results 2 years postop
Allegheny Health Network incorporates MAKOplasty
